phendimetrazine tartrate

phendimetrazine tartrate

a sympathomimetic amine used as an anorectic agent.
indications It is prescribed to reduce appetite during the first few weeks of dieting during treatment of exogenous obesity. Its beneficial effects slowly disappear over 3 to 12 weeks.
contraindications Cardiovascular disease, hypertension, hyperthyroidism, glaucoma, nervousness, a history of drug abuse, concomitant administration of central nervous system stimulants or monoamine oxidase inhibitors, or known hypersensitivity to this drug prohibits its use.
adverse effects Among the more serious adverse effects are central nervous system stimulation, elevated blood pressure, insomnia, dry mouth, and tolerance to the drug.


A short-acting central amphetamine-type anorexiant.

Adverse effects
Cardiotoxicity—tachycardia, arrhythmias, hypertension, cardiovascular collapse; nervous system—tremor, restlessness, agitation, insomnia, increased motor activity, headache, convulsions, coma, hyperreflexia; rarely, CVA, cerebral vasculitis; high risk of dependency, abuse.

phendimetrazine tartrate (fen´dīmet´rəzēn´ tar´trāt),

n brand names: Adipost, Anorex SR, Appecon, Obalan, others;
drug class: anorexiant, amphetamine-like Controlled Substance Schedule III;
action: exact mechanism of action of appetite suppression is unknown but may have an effect on the satiety center of the hypothalamus;
use: exogenous obesity.
Mentioned in ?
References in periodicals archive ?
Food and Drug Administration (FDA) for Phendimetrazine Tartrate Tablets USP, 35mg.
The Phendimetrazine Tartrate approval is from an Elite ANDA filed approximately six years ago.
An ANDA approval for Phendimetrazine Tartrate at the end of 2017 was a welcome occurrence," commented Nasrat Hakim, President and CEO of Elite.